Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TOBI Podhaler 224 Capsule Monthly Pack

Known as: TOBRAMYCIN 28 mg RESPIRATORY (INHALATION) CAPSULE [TOBI Podhaler]_#1, {224 (Tobramycin 28 MG Inhalant Powder [Tobi]) } Pack [TOBI Podhaler Kit], TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules) 
 
National Institutes of Health

Related topics

Related topics

7 relations
1,2-distearoyllecithinCalcium ChloridePackSulfuric acid
Expand

Broader (2)

Tobramycin 28 MG Inhalant Powder [Tobi]{224 (Tobramycin 28 MG Inhalant Powder) } Pack

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
BACKGROUND A high treatment burden with nebulised therapies in cystic fibrosis (CF) patients is the major limitation for… Expand
Is this relevant?
2017
2017
Physical Characterization of Tobramycin Inhalation Powder: II. State Diagram of an Amorphous Engineered Particle Formulation.
Tobramycin Inhalation Powder (TIP) is a spray-dried engineered particle formulation used in TOBI Podhaler, a drug-device… Expand
Is this relevant?
2016
2016
The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis.
The aerosol performance and delivery characteristics of tobramycin for the treatment of respiratory infection were evaluated… Expand
Is this relevant?
2015
2015
ePS03.3 Longer term tolerance and likely adherence to TOBI Podhaler in CF adults
Background In a 6-month clinical trial, TOBI Podhaler (TIP) has been shown to be safe and generally well tolerated compared to… Expand
Is this relevant?
2014
2014
Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
Tobramycin powder for inhalation (TOBI Podhaler or TIP) is approved for the treatment of Pseudomonas aeruginosa airway infection… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Review
2013
Review
2013
Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
  • The Medical letter on drugs and therapeutics
  • 2013
    • Corpus ID: 9856913
 
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
BACKGROUND A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • table 3
Is this relevant?
2011
2011
216 Long-term inhaled ampicillin for the treatment of methicillin-susceptible Staphylococcus aureus bronchopulmonary infection in cystic fibrosis patients
215 Adherence with TOBI® among cystic fibrosis patients with Pseudomonas aeruginosa infection V.N. Joish1, S.S. Sansgiry2, S.H… Expand
Is this relevant?
2008
2008
Impacto clínico y evolución microbiológica tras tratamiento con tobramicina inhalada en bronquiectasias colonizadas por Pseudomonas aeruginosa.
espanolFUNDAMENTO: Evaluar la eficacia de tobramicina nebulizada �TOBI®� en la modificacion de la historia natural de la… Expand
Is this relevant?
1982
1982
SEDIMENTARY ENVIRONMENT AND PETROLOGY OF THE AIN TOBI FORMATION, TRIPOLITANIA, LIBYA
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE